vs

Side-by-side financial comparison of REPLIGEN CORP (RGEN) and INNOVATE Corp. (VATE). Click either name above to swap in a different company.

INNOVATE Corp. is the larger business by last-quarter revenue ($382.7M vs $197.9M, roughly 1.9× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs -1.9%, a 8.6% gap on every dollar of revenue. On growth, INNOVATE Corp. posted the faster year-over-year revenue change (61.7% vs 13.6%). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 10.2%).

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

Innovate Corp. is an American public financial services company founded in 1994.

RGEN vs VATE — Head-to-Head

Bigger by revenue
VATE
VATE
1.9× larger
VATE
$382.7M
$197.9M
RGEN
Growing faster (revenue YoY)
VATE
VATE
+48.1% gap
VATE
61.7%
13.6%
RGEN
Higher net margin
RGEN
RGEN
8.6% more per $
RGEN
6.7%
-1.9%
VATE
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
10.2%
VATE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RGEN
RGEN
VATE
VATE
Revenue
$197.9M
$382.7M
Net Profit
$13.3M
$-7.4M
Gross Margin
52.5%
15.4%
Operating Margin
9.0%
3.7%
Net Margin
6.7%
-1.9%
Revenue YoY
13.6%
61.7%
Net Profit YoY
143.9%
55.4%
EPS (diluted)
$0.24
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RGEN
RGEN
VATE
VATE
Q4 25
$197.9M
$382.7M
Q3 25
$188.8M
$347.1M
Q2 25
$182.4M
$242.0M
Q1 25
$169.2M
$274.2M
Q4 24
$174.1M
$236.6M
Q3 24
$154.9M
$242.2M
Q2 24
$154.1M
$313.1M
Q1 24
$151.3M
$315.2M
Net Profit
RGEN
RGEN
VATE
VATE
Q4 25
$13.3M
$-7.4M
Q3 25
$14.9M
$-8.9M
Q2 25
$14.9M
$-19.8M
Q1 25
$5.8M
$-24.5M
Q4 24
$-30.3M
$-16.6M
Q3 24
$-654.0K
$-15.0M
Q2 24
$3.3M
$14.4M
Q1 24
$2.1M
$-17.4M
Gross Margin
RGEN
RGEN
VATE
VATE
Q4 25
52.5%
15.4%
Q3 25
53.2%
14.3%
Q2 25
50.0%
18.8%
Q1 25
53.6%
16.6%
Q4 24
26.1%
19.6%
Q3 24
50.0%
19.9%
Q2 24
49.8%
21.0%
Q1 24
49.5%
15.4%
Operating Margin
RGEN
RGEN
VATE
VATE
Q4 25
9.0%
3.7%
Q3 25
8.9%
1.8%
Q2 25
7.6%
2.0%
Q1 25
3.9%
1.2%
Q4 24
-17.7%
1.1%
Q3 24
-5.1%
2.4%
Q2 24
1.0%
9.2%
Q1 24
1.3%
0.9%
Net Margin
RGEN
RGEN
VATE
VATE
Q4 25
6.7%
-1.9%
Q3 25
7.9%
-2.6%
Q2 25
8.2%
-8.2%
Q1 25
3.4%
-8.9%
Q4 24
-17.4%
-7.0%
Q3 24
-0.4%
-6.2%
Q2 24
2.2%
4.6%
Q1 24
1.4%
-5.5%
EPS (diluted)
RGEN
RGEN
VATE
VATE
Q4 25
$0.24
$-0.57
Q3 25
$0.26
$-0.71
Q2 25
$0.26
$-1.67
Q1 25
$0.10
$-1.89
Q4 24
$-0.55
$-0.72
Q3 24
$-0.01
$-1.18
Q2 24
$0.06
$1.03
Q1 24
$0.04
$-2.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RGEN
RGEN
VATE
VATE
Cash + ST InvestmentsLiquidity on hand
$767.6M
$112.1M
Total DebtLower is stronger
$542.2M
$80.3M
Stockholders' EquityBook value
$2.1B
$-240.1M
Total Assets
$2.9B
$950.1M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RGEN
RGEN
VATE
VATE
Q4 25
$767.6M
$112.1M
Q3 25
$748.7M
$35.5M
Q2 25
$708.9M
$33.4M
Q1 25
$697.2M
$33.3M
Q4 24
$757.4M
$48.8M
Q3 24
$784.0M
$51.0M
Q2 24
$809.1M
$80.2M
Q1 24
$780.6M
$38.4M
Total Debt
RGEN
RGEN
VATE
VATE
Q4 25
$542.2M
$80.3M
Q3 25
$537.9M
$97.3M
Q2 25
$160.1M
Q1 25
$139.9M
Q4 24
$525.6M
$500.6M
Q3 24
$502.4M
Q2 24
$638.3M
Q1 24
$641.5M
Stockholders' Equity
RGEN
RGEN
VATE
VATE
Q4 25
$2.1B
$-240.1M
Q3 25
$2.1B
$-233.3M
Q2 25
$2.1B
$-224.8M
Q1 25
$2.0B
$-204.2M
Q4 24
$2.0B
$-180.4M
Q3 24
$2.0B
$-163.1M
Q2 24
$2.0B
$-149.0M
Q1 24
$2.0B
$-184.4M
Total Assets
RGEN
RGEN
VATE
VATE
Q4 25
$2.9B
$950.1M
Q3 25
$2.9B
$913.2M
Q2 25
$2.9B
$890.9M
Q1 25
$2.9B
$868.0M
Q4 24
$2.8B
$891.1M
Q3 24
$2.8B
$897.2M
Q2 24
$2.9B
$898.9M
Q1 24
$2.8B
$943.5M
Debt / Equity
RGEN
RGEN
VATE
VATE
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RGEN
RGEN
VATE
VATE
Operating Cash FlowLast quarter
$25.7M
$101.1M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RGEN
RGEN
VATE
VATE
Q4 25
$25.7M
$101.1M
Q3 25
$48.1M
$19.2M
Q2 25
$28.6M
$40.4M
Q1 25
$15.0M
$-14.1M
Q4 24
$39.2M
$41.4M
Q3 24
$49.3M
$-28.4M
Q2 24
$42.2M
$21.5M
Q1 24
$44.7M
$-25.4M
Free Cash Flow
RGEN
RGEN
VATE
VATE
Q4 25
$17.6M
Q3 25
$43.4M
$19.0M
Q2 25
$21.5M
Q1 25
$11.4M
$-18.8M
Q4 24
$33.6M
$34.2M
Q3 24
$42.3M
$-31.5M
Q2 24
$37.4M
$18.4M
Q1 24
$36.4M
$-31.0M
FCF Margin
RGEN
RGEN
VATE
VATE
Q4 25
8.9%
Q3 25
23.0%
5.5%
Q2 25
11.8%
Q1 25
6.8%
-6.9%
Q4 24
19.3%
14.5%
Q3 24
27.3%
-13.0%
Q2 24
24.3%
5.9%
Q1 24
24.0%
-9.8%
Capex Intensity
RGEN
RGEN
VATE
VATE
Q4 25
4.1%
Q3 25
2.5%
0.1%
Q2 25
3.9%
Q1 25
2.1%
1.7%
Q4 24
3.2%
3.0%
Q3 24
4.5%
1.3%
Q2 24
3.1%
1.0%
Q1 24
5.5%
1.8%
Cash Conversion
RGEN
RGEN
VATE
VATE
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
1.49×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RGEN
RGEN

Segment breakdown not available.

VATE
VATE

Commercial Revenue$126.1M33%
Industrial Revenue$87.5M23%
Transportation Revenue$58.4M15%
Healthcare Revenue$48.4M13%
Government Revenue$44.3M12%
Energy Revenue$8.0M2%
Broadcast Station Revenue$5.7M1%
Systems And Consumables Revenue$3.1M1%
Leisure Revenue$200.0K0%

Related Comparisons